A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review)

Huang,Shuhao; Qin,Zihao; Wang,Feiyang; Kang,Yiping; Ren,Biqiong

doi:10.3892/or.2024.8796

A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review)

Authors:
- Shuhao Huang
- Zihao Qin
- Feiyang Wang
- Yiping Kang
- Biqiong Ren
View Affiliations

Affiliations: Hunan Center for Clinical Laboratory, Second People's Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China
Published online on: August 14, 2024 https://doi.org/10.3892/or.2024.8796
Article Number: 137
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The immune system is integral to the surveillance and eradication of tumor cells. Interactions between the natural killer group 2 member D (NKG2D) receptor and its ligands (NKG2DLs) are vital for activating NKG2D receptor‑positive immune cells, such as natural killer cells. This activation enables these cells to identify and destroy tumor cells presenting with NKG2DLs, which is an essential aspect of tumor immunity. However, tumor immune escape is facilitated by soluble NKG2DL (sNKG2DL) shed from the surface of tumor cells. The production of sNKG2DL is predominantly regulated by metalloproteinases [a disintegrin and metalloproteinases (ADAM) and matrix metalloproteinase (MMP) families] and exosomes. sNKG2DL not only diminish immune recognition on the tumor cell surface but also suppress the function of immune cells, such as NK cells, and reduce the expression of the NKG2D receptor. This process promotes immune evasion, progression, and metastasis of tumors. In this review, an in‑depth summary of the mechanisms and factors that influence sNKG2DL production and their contribution to immune suppression within the tumor microenvironment are provided. Furthermore, due to the significant link between sNKG2DLs and tumor progression and metastasis, they have great potential as novel biomarkers. Detectable via liquid biopsies, sNKG2DLs could assess tumor malignancy and prognosis, and act as pivotal targets for immunotherapy. This could lead to the discovery of new drugs or the enhancement of existing treatments. Thus, the application of sNKG2DLs in clinical oncology was explored, offering substantial theoretical support for the development of innovative immunotherapeutic strategies for sNKG2DLs.

View Figures

View References

1	Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, Wang Y, Xiong F, Guo C, Li Y, et al: Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 18:292019. View Article : Google Scholar : PubMed/NCBI
2	Tan G, Spillane KM and Maher J: The role and regulation of the NKG2D/NKG2D ligand system in cancer. Biology (Basel). 12:10792023.PubMed/NCBI
3	Ullrich E, Koch J, Cerwenka A and Steinle A: New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2:e260972013. View Article : Google Scholar : PubMed/NCBI
4	Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 3:781–790. 2003. View Article : Google Scholar : PubMed/NCBI
5	Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, Cerboni C and Santoni A: NKG2D and its ligands: ‘One for all, all for one’. Front Immunol. 9:4762018. View Article : Google Scholar : PubMed/NCBI
6	Tchacrome I, Zhu Q, Saleh MA and Zou Y: Diseases association with the polymorphic major histocompatibility complex class I related chain a: MICA gene. Transpl Immunol. 75:1016652022. View Article : Google Scholar : PubMed/NCBI
7	Maurer S, Zhong X, Prada BD, Mascarenhas J and de Andrade LF: The latest breakthroughs in immunotherapy for acute myeloid leukemia, with a special focus on NKG2D ligands. Int J Mol Sci. 23:159072022. View Article : Google Scholar : PubMed/NCBI
8	Campos-Silva C, López-Borrego S, Felgueres MJ, Esteso G and Vales-Gomez M: NKG2D ligands in liquid biopsy: The importance of soluble and vesicle-bound proteins for immune modulation. Crit Rev Immunol. 42:21–40. 2022. View Article : Google Scholar : PubMed/NCBI
9	Lanier LL: NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 3:575–582. 2015. View Article : Google Scholar : PubMed/NCBI
10	Touboul R, Zaravinos A and Bonavida B: Defective natural killer cells in melanoma: Role of NKG2D in pathogenesis and immunotherapy. Crit Rev Immunol. 41:45–76. 2021. View Article : Google Scholar : PubMed/NCBI
11	Jones AB, Rocco A, Lamb LS, Friedman GK and Hjelmeland AB: Regulation of NKG2D stress ligands and its relevance in cancer progression. Cancers (Basel). 14:23392022. View Article : Google Scholar : PubMed/NCBI
12	Groh V, Bahram S, Bauer S, Herman A, Beauchamp M and Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA. 93:12445–12450. 1996. View Article : Google Scholar : PubMed/NCBI
13	Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M and Chalupny NJ: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 14:123–133. 2001. View Article : Google Scholar : PubMed/NCBI
14	Groh V, Steinle A, Bauer S and Spies T: Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science. 279:1737–1740. 1998. View Article : Google Scholar : PubMed/NCBI
15	Venkataraman GM, Suciu D, Groh V, Boss JM and Spies T: Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol. 178:961–969. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004. View Article : Google Scholar : PubMed/NCBI
17	Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG and Cerwenka A: Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 71:5998–6009. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zhao Y, Simon M, Seluanov A and Gorbunova V: DNA damage and repair in age-related inflammation. Nat Rev Immunol. 23:75–89. 2023. View Article : Google Scholar : PubMed/NCBI
19	Lin D, Lavender H, Soilleux EJ and O'Callaghan CA: NF-κB regulates MICA gene transcription in endothelial cell through a genetically inhibitable control site. J Biol Chem. 287:4299–4310. 2012. View Article : Google Scholar : PubMed/NCBI
20	Schrambach S, Ardizzone M, Leymarie V, Sibilia J and Bahram S: In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS One. 2:e5182007. View Article : Google Scholar : PubMed/NCBI
21	Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M and Mandelboim O: Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol. 9:1065–1073. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yadav D, Ngolab J, Lim RSH, Krishnamurthy S and Bui JD: Cutting edge: Down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol. 182:39–43. 2009. View Article : Google Scholar : PubMed/NCBI
23	Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D and Paschen A: Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 72:460–471. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M and Imamura M: Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia. 21:2103–2108. 2007. View Article : Google Scholar : PubMed/NCBI
25	Morimoto Y, Yamashita N, Daimon T, Hirose H, Yamano S, Haratake N, Ishikawa S, Bhattacharya A, Fushimi A, Ahmad R, et al: MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells. J Immunother Cancer. 11:e0062382023. View Article : Google Scholar : PubMed/NCBI
26	Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, et al: IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 18:1402–1412. 2016. View Article : Google Scholar : PubMed/NCBI
27	Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y, Yamin R, Vitenshtein A, Stanietsky N, Bar-Mag T, et al: MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res. 72:5463–5472. 2012. View Article : Google Scholar : PubMed/NCBI
28	Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M, Reifenberger G and Roth P: MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget. 5:7651–7662. 2014. View Article : Google Scholar : PubMed/NCBI
29	Breunig C, Pahl J, Küblbeck M, Miller M, Antonelli D, Erdem N, Wirth C, Will R, Bott A, Cerwenka A and Wiemann S: MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell Death Dis. 8:e29732017. View Article : Google Scholar : PubMed/NCBI
30	Eagle RA, Flack G, Warford A, Martínez-Borra J, Jafferji I, Traherne JA, Ohashi M, Boyle LH, Barrow AD, Caillat-Zucman S, et al: Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G. PLoS One. 4:e45032009. View Article : Google Scholar : PubMed/NCBI
31	Fernández-Messina L, Reyburn HT and Valés-Gómez M: A short half-life of ULBP1 at the cell surface due to internalization and proteosomal degradation. Immunol Cell Biol. 94:479–485. 2016. View Article : Google Scholar : PubMed/NCBI
32	Agüera-González S, Boutet P, Reyburn HT and Valés-Gómez M: Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol. 182:4800–4808. 2009. View Article : Google Scholar : PubMed/NCBI
33	Gomis-Rüth FX: Structural aspects of the metzincin clan of metalloendopeptidases. Mol Biotechnol. 24:157–202. 2003. View Article : Google Scholar : PubMed/NCBI
34	Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008. View Article : Google Scholar : PubMed/NCBI
35	Cui N, Hu M and Khalil RA: Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 147:1–73. 2017. View Article : Google Scholar : PubMed/NCBI
36	Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, Strong RK, Groh V and Spies T: Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 447:482–486. 2007. View Article : Google Scholar : PubMed/NCBI
37	Wang X, Lundgren AD, Singh P, Goodlett DR, Plymate SR and Wu JD: An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding. Biochem Biophys Res Commun. 387:476–481. 2009. View Article : Google Scholar : PubMed/NCBI
38	Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG and Steinle A: Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 68:6368–6376. 2008. View Article : Google Scholar : PubMed/NCBI
39	Waldhauer I and Steinle A: Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 66:2520–2526. 2006. View Article : Google Scholar : PubMed/NCBI
40	Boutet P, Agüera-González S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT and Valés-Gómez M: Cutting edge: The metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol. 182:49–53. 2009. View Article : Google Scholar : PubMed/NCBI
41	Fernández-Messina L, Ashiru O, Boutet P, Agüera-González S, Skepper JN, Reyburn HT and Valés-Gómez M: Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem. 285:8543–8551. 2010. View Article : Google Scholar : PubMed/NCBI
42	Raneros AB, Minguela A, Rodriguez RM, Colado E, Bernal T, Anguita E, Mogorron AV, Gil AC, Vidal-Castiñeira JR, Márquez-Kisinousky L, et al: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. Oncotarget. 8:31959–31976. 2017. View Article : Google Scholar : PubMed/NCBI
43	Brown DA: Lipid rafts, detergent-resistant membranes, and raft targeting signals. Physiology (Bethesda). 21:430–439. 2006.PubMed/NCBI
44	de Gassart A, Geminard C, Fevrier B, Raposo G and Vidal M: Lipid raft-associated protein sorting in exosomes. Blood. 102:4336–4344. 2003. View Article : Google Scholar : PubMed/NCBI
45	Ashiru O, Boutet P, Fernández-Messina L, Agüera-González S, Skepper JN, Valés-Gómez M and Reyburn HT: Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 70:481–489. 2010. View Article : Google Scholar : PubMed/NCBI
46	Hedlund M, Nagaeva O, Kargl D, Baranov V and Mincheva-Nilsson L: Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One. 6:e168992011. View Article : Google Scholar : PubMed/NCBI
47	Agüera-González S, Gross CC, Fernández-Messina L, Ashiru O, Esteso G, Hang HC, Reyburn HT, Long EO and Valés-Gómez M: Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur J Immunol. 41:3667–3676. 2011. View Article : Google Scholar : PubMed/NCBI
48	Eleme K, Taner SB, Onfelt B, Collinson LM, McCann FE, Chalupny NJ, Cosman D, Hopkins C, Magee AI and Davis DM: Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J Exp Med. 199:1005–1010. 2004. View Article : Google Scholar : PubMed/NCBI
49	Bacon L, Eagle RA, Meyer M, Easom N, Young NT and Trowsdale J: Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol. 173:1078–1084. 2004. View Article : Google Scholar : PubMed/NCBI
50	Cao W, Xi X, Hao Z, Li W, Kong Y, Cui L, Ma C, Ba D and He W: RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J Biol Chem. 282:18922–18928. 2007. View Article : Google Scholar : PubMed/NCBI
51	Zingoni A, Vulpis E, Cecere F, Amendola MG, Fuerst D, Saribekyan T, Achour A, Sandalova T, Nardone I, Peri A, et al: MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma. Front Immunol. 9:9262018. View Article : Google Scholar : PubMed/NCBI
52	Toledo-Stuardo K, Ribeiro CH, Canals A, Morales M, Gárate V, Rodríguez-Siza J, Tello S, Bustamante M, Armisen R, Matthies DJ, et al: Major histocompatibility complex class I-related chain A (MICA) allelic variants associate with susceptibility and prognosis of gastric cancer. Front Immunol. 12:6455282021. View Article : Google Scholar : PubMed/NCBI
53	Ashiru O, López-Cobo S, Fernández-Messina L, Pontes-Quero S, Pandolfi R, Reyburn HT and Valés-Gómez M: A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008. Biochem J. 454:295–302. 2013. View Article : Google Scholar : PubMed/NCBI
54	López-Cobo S, Campos-Silva C and Valés-Gómez M: Glycosyl-phosphatidyl-inositol (GPI)-anchors and metalloproteases: Their roles in the regulation of exosome composition and NKG2D-mediated immune recognition. Front Cell Dev Biol. 4:972016. View Article : Google Scholar : PubMed/NCBI
55	Isernhagen A, Schilling D, Monecke S, Shah P, Elsner L, Walter L, Multhoff G and Dressel R: The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA. Immunogenetics. 68:109–123. 2016. View Article : Google Scholar : PubMed/NCBI
56	Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, et al: Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 43:455–458. 2011. View Article : Google Scholar : PubMed/NCBI
57	Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR and Graham CH: Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res. 71:7433–7441. 2011. View Article : Google Scholar : PubMed/NCBI
58	Ou ZL, Luo Z, Wei W, Liang S, Gao TL and Lu YB: Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: Role of circ_0000977/miR-153 axis. RNA Biol. 16:1592–1603. 2019. View Article : Google Scholar : PubMed/NCBI
59	Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K, Ferbeyre G, et al: Cellular senescence: Defining a path forward. Cell. 179:813–827. 2019. View Article : Google Scholar : PubMed/NCBI
60	Zhang Y, Hu R, Xi B, Nie D, Xu H and Liu A: Mechanisms of senescence-related NKG2D ligands release and immune escape induced by chemotherapy in neuroblastoma cells. Front Cell Dev Biol. 10:8294042022. View Article : Google Scholar : PubMed/NCBI
61	Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A and Hayashi N: Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology. 51:1264–1273. 2010. View Article : Google Scholar : PubMed/NCBI
62	Ziani L, Safta-Saadoun TB, Gourbeix J, Cavalcanti A, Robert C, Favre G, Chouaib S and Thiery J: Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. Oncotarget. 8:19780–19794. 2017. View Article : Google Scholar : PubMed/NCBI
63	Maurer S, Kropp KN, Klein G, Steinle A, Haen SP, Walz JS, Hinterleitner C, Märklin M, Kopp HG and Salih HR: Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology. 7:e13648272017. View Article : Google Scholar : PubMed/NCBI
64	Zocchi MR, Catellani S, Canevali P, Tavella S, Garuti A, Villaggio B, Zunino A, Gobbi M, Fraternali-Orcioni G, Kunkl A, et al: High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood. 119:1479–1489. 2012. View Article : Google Scholar : PubMed/NCBI
65	Vandooren J, Van den Steen PE and Opdenakker G: Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev Biochem Mol Biol. 48:222–272. 2013. View Article : Google Scholar : PubMed/NCBI
66	Kohga K, Tatsumi T, Tsunematsu H, Aono S, Shimizu S, Kodama T, Hikita H, Yamamoto M, Oze T, Aketa H, et al: Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunol Immunother. 61:1425–1432. 2012. View Article : Google Scholar : PubMed/NCBI
67	Lu Y, Jiang F, Zheng X, Katakowski M, Buller B, To SS and Chopp M: TGF-β1 promotes motility and invasiveness of glioma cells through activation of ADAM17. Oncol Rep. 25:1329–1335. 2011.PubMed/NCBI
68	Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M and Friese MA: TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 129:2416–2425. 2006. View Article : Google Scholar : PubMed/NCBI
69	Fang X, Guo L, Xing Z, Shi L, Liang H, Li A, Kuang C, Tao B and Yang Q: IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D ligand via ADAM10. Pharmacol Res. 177:1061322022. View Article : Google Scholar : PubMed/NCBI
70	Del Toro-Arreola S, Arreygue-Garcia N, Aguilar-Lemarroy A, Cid-Arregui A, Jimenez-Perez M, Haramati J, Barros-Nuñez P, Gonzalez-Ramella O, Del Toro-Arreola A, Ortiz-Lazareno P, et al: MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines. Cancer Cell Int. 11:152011. View Article : Google Scholar : PubMed/NCBI
71	Hilpert J, Grosse-Hovest L, Grünebach F, Buechele C, Nuebling T, Raum T, Steinle A and Salih HR: Comprehensive analysis of NKG2D ligand expression and release in leukemia: Implications for NKG2D-mediated NK cell responses. J Immunol. 189:1360–1371. 2012. View Article : Google Scholar : PubMed/NCBI
72	Arai J, Goto K, Otoyama Y, Nakajima Y, Sugiura I, Kajiwara A, Tojo M, Ichikawa Y, Uozumi S, Shimozuma Y, et al: Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding. Cancer Immunol Immunother. 70:203–213. 2021. View Article : Google Scholar : PubMed/NCBI
73	Molfetta R, Quatrini L, Zitti B, Capuano C, Galandrini R, Santoni A and Paolini R: Regulation of NKG2D expression and signaling by endocytosis. Trends Immunol. 37:790–802. 2016. View Article : Google Scholar : PubMed/NCBI
74	Clayton A and Tabi Z: Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis. 34:206–213. 2005. View Article : Google Scholar : PubMed/NCBI
75	Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, Galandrini R, Santoni A and Paolini R: c-Cbl regulates MICA-but not ULBP2-induced NKG2D down-modulation in human NK cells. Eur J Immunol. 44:2761–2770. 2014. View Article : Google Scholar : PubMed/NCBI
76	Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N and Raulet DH: Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science. 348:136–139. 2015. View Article : Google Scholar : PubMed/NCBI
77	Vulpis E, Loconte L, Peri A, Molfetta R, Caracciolo G, Masuelli L, Tomaipitinca L, Peruzzi G, Petillo S, Petrucci MT, et al: Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance. J Extracell Vesicles. 11:e121762022. View Article : Google Scholar : PubMed/NCBI
78	Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S and Hayashi N: Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol. 43:1013–1020. 2005. View Article : Google Scholar : PubMed/NCBI
79	Zhang J, Liu D, Li G, Staveley-O'Carroll KF, Graff JN, Li Z and Wu JD: Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Sci Adv. 3:e16021332017. View Article : Google Scholar : PubMed/NCBI
80	Xiao G, Wang X, Sheng J, Lu S, Yu X and Wu JD: Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype. J Hematol Oncol. 8:132015. View Article : Google Scholar : PubMed/NCBI
81	Yamaguchi K, Chikumi H, Shimizu A, Takata M, Kinoshita N, Hashimoto K, Nakamoto M, Matsunaga S, Kurai J, Miyake N, et al: Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Cancer Sci. 103:1405–1413. 2012. View Article : Google Scholar : PubMed/NCBI
82	Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O and Heinemann V: Tumor markers in pancreatic cancer: A European group on tumor markers (EGTM) status report. Ann Oncol. 21:441–447. 2010. View Article : Google Scholar : PubMed/NCBI
83	Chung HW and Lim JB: Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma. Cancer Sci. 102:1673–1679. 2011. View Article : Google Scholar : PubMed/NCBI
84	Chung HW, Jang S and Lim JB: Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma. Cancer. 119:233–244. 2013. View Article : Google Scholar : PubMed/NCBI
85	Qiu Y, Zhao YK, Yuan GJ and Zhu QG: Clinical significance of soluble major histocompatibility complex class I chain-related a in renal cell carcinoma patients. Asian Pac J Cancer Prev. 14:5651–5655. 2013. View Article : Google Scholar : PubMed/NCBI
86	Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A and Salih HR: Soluble MICA in malignant diseases. Int J Cancer. 118:684–687. 2006. View Article : Google Scholar : PubMed/NCBI
87	Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A and Salih HR: Soluble MICB in malignant diseases: Analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother. 55:1584–1589. 2006. View Article : Google Scholar : PubMed/NCBI
88	Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 114:560–568. 2004. View Article : Google Scholar : PubMed/NCBI
89	Jiang X, Huang JF, Huo Z, Zhang Q, Jiang Y, Wu X, Li Y, Jiang G, Zeng L, Yan XX, et al: Elevation of soluble major histocompatibility complex class I related chain A protein in malignant and infectious diseases in Chinese patients. BMC Immunol. 13:622012. View Article : Google Scholar : PubMed/NCBI
90	Mantovani S, Varchetta S, Mele D, Donadon M, Torzilli G, Soldani C, Franceschini B, Porta C, Chiellino S, Pedrazzoli P, et al: An anti-MICA/B antibody and IL-15 rescue altered NKG2D-dependent NK cell responses in hepatocellular carcinoma. Cancers (Basel). 12:35832020. View Article : Google Scholar : PubMed/NCBI
91	Kshersagar J, Damle MN, Bedge P, Jagdale R, Tardalkar K, Jadhav D, Jagadale S, Toro Y, Sharma R and Joshi MG: Downregulation of MICA/B tumor surface expressions and augmented soluble MICA serum levels correlate with disease stage in breast cancer. Breast Dis. 41:471–480. 2022. View Article : Google Scholar : PubMed/NCBI
92	Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miyagi T, Hiramatsu N, Kanto T, Kasugai T, Katayama K, Kato M and Hayashi N: Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci. 99:1643–1649. 2008. View Article : Google Scholar : PubMed/NCBI
93	Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR and Dranoff G: MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA. 105:1285–1290. 2008. View Article : Google Scholar : PubMed/NCBI
94	Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, et al: Differential clinical significance of individual NKG2D ligands in melanoma: Soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res. 15:5208–5215. 2009. View Article : Google Scholar : PubMed/NCBI
95	Zhao Y, Chen N, Yu Y, Zhou L, Niu C, Liu Y, Tian H, Lv Z, Han F and Cui J: Prognostic value of MICA/B in cancers: A systematic review and meta-analysis. Oncotarget. 8:96384–96395. 2017. View Article : Google Scholar : PubMed/NCBI
96	Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J and Prinz RA: Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer. 11:1942011. View Article : Google Scholar : PubMed/NCBI
97	Wang LP, Niu H, Xia YF, Han YL, Niu P, Wang HY and Zhou QL: Prognostic significance of serum sMICA levels in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 19:2226–2230. 2015.PubMed/NCBI
98	Xing S, Zhu Y and Sun Y: Serum sMICA as biomarker in detection of non-small-cell lung carcinoma. Br J Biomed Sci. 75:50–52. 2018. View Article : Google Scholar : PubMed/NCBI
99	Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T, Müller-Runte A, Lampe K, Beutner D, Quaas A, et al: Natural killer group 2D ligand depletion reconstitutes natural killer cell immunosurveillance of head and neck squamous cell carcinoma. Front Immunol. 8:3872017. View Article : Google Scholar : PubMed/NCBI
100	Chen JL, Chang CC, Huang YS, Kuo HY, Chen TY, Wang CW, Kuo SH and Lin YL: Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy. PLoS One. 13:e02022242018. View Article : Google Scholar : PubMed/NCBI
101	Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC and Xia JC: Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. Chin J Cancer. 32:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
102	Cheung PF, Yip CW, Wong NC, Fong DY, Ng LW, Wan AM, Wong CK, Cheung TT, Ng IO, Poon RT, et al: Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. Cancer Immunol Res. 2:1209–1219. 2014. View Article : Google Scholar : PubMed/NCBI
103	Roshani R, Boroujerdnia MG, Talaiezadeh AH and Khodadadi A: Assessment of changes in expression and presentation of NKG2D under influence of MICA serum factor in different stages of breast cancer. Tumour Biol. 37:6953–6962. 2016. View Article : Google Scholar : PubMed/NCBI
104	Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, Ellis I and Durrant LG: Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun. 7:172007.PubMed/NCBI
105	Zhao YK, Jia CM, Yuan GJ, Liu W, Qiu Y and Zhu QG: Expression and clinical value of the soluble major histocompatibility complex class I-related chain A molecule in the serum of patients with renal tumors. Genet Mol Res. 14:7233–7240. 2015. View Article : Google Scholar : PubMed/NCBI
106	Samuels S, Ferns DM, Meijer D, van Straalen JP, Buist MR, Zijlmans HJ, Kenter GG and Jordanova ES: High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. Tissue Antigens. 85:476–483. 2015. View Article : Google Scholar : PubMed/NCBI
107	Märten A, von Lilienfeld-Toal M, Büchler MW and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer. 119:2359–2365. 2006. View Article : Google Scholar : PubMed/NCBI
108	Chen J, Xu H and Zhu XX: Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer. Ther Clin Risk Manag. 12:11–18. 2015.PubMed/NCBI
109	Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J and Sun W: Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol. 28:466–474. 2011. View Article : Google Scholar : PubMed/NCBI
110	Ben Chaaben A, Ouni N, Douik H, Ayari F, Abaza H, Mamoghli T, Harzallah L, Fortier C, Boukouaci W, Krishnamoorthy R, et al: Soluble MICA and anti-MICA antibodies as biomarkers of nasopharyngeal carcinoma disease. Immunol Invest. 49:498–509. 2020. View Article : Google Scholar : PubMed/NCBI
111	Tamaki S, Sanefuzi N, Kawakami M, Aoki K, Imai Y, Yamanaka Y, Yamamoto K, Ishitani A, Hatake K and Kirita T: Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum Immunol. 69:88–93. 2008. View Article : Google Scholar : PubMed/NCBI
112	Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V, et al: Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 8:162008. View Article : Google Scholar : PubMed/NCBI
113	Nückel H, Switala M, Sellmann L, Horn PA, Dürig J, Dührsen U, Küppers R, Grosse-Wilde H and Rebmann V: The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia. 24:1152–1159. 2010. View Article : Google Scholar : PubMed/NCBI
114	Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo AM, Parmiani G and Maio M: Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. Oncoimmunology. 5:e10710072015. View Article : Google Scholar : PubMed/NCBI
115	Rebmann V, Schütt P, Brandhorst D, Opalka B, Moritz T, Nowrousian MR and Grosse-Wilde H: Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol. 123:114–120. 2007. View Article : Google Scholar : PubMed/NCBI
116	Zhang T, Barber A and Sentman CL: Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66:5927–5933. 2006. View Article : Google Scholar : PubMed/NCBI
117	Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, et al: Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol Res. 7:100–112. 2019. View Article : Google Scholar : PubMed/NCBI
118	Liu R, Luo Q, Luo W, Wan L, Zhu Q, Yin X, Lu X, Song Z, Wei L, Xiang Z and Zou Y: A soluble NK-CAR mediates the specific cytotoxicity of NK cells toward the target CD20⁺ lymphoma cells. Aging Dis. 13:1576–1588. 2022. View Article : Google Scholar : PubMed/NCBI
119	Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ, et al: Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 359:1537–1542. 2018. View Article : Google Scholar : PubMed/NCBI
120	Du C, Bevers J III, Cook R, Lombana TN, Rajasekaran K, Matsumoto M, Spiess C, Kim JM and Ye Z: MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner. J Immunother Cancer. 7:2072019. View Article : Google Scholar : PubMed/NCBI
121	Alves da Silva PH, Xing S, Kotini AG, Papapetrou EP, Song X, Wucherpfennig KW, Mascarenhas J and Ferrari de Andrade L: MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood. 139:205–216. 2022. View Article : Google Scholar : PubMed/NCBI
122	Ferrari de Andrade L, Kumar S, Luoma AM, Ito Y, Alves da Silva PH, Pan D, Pyrdol JW, Yoon CH and Wucherpfennig KW: Inhibition of MICA and MICB shedding elicits NK-cell-mediated immunity against tumors resistant to cytotoxic T cells. Cancer Immunol Res. 8:769–780. 2020. View Article : Google Scholar : PubMed/NCBI
123	Badrinath S, Dellacherie MO, Li A, Zheng S, Zhang X, Sobral M, Pyrdol JW, Smith KL, Lu Y, Haag S, et al: A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 606:992–998. 2022. View Article : Google Scholar : PubMed/NCBI
124	Lu S, Zhang J, Liu D, Li G, Staveley-O'Carroll KF, Li Z and Wu JD: Nonblocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive antitumor responses and eliminates primary and metastatic tumors. Clin Cancer Res. 21:4819–4830. 2015. View Article : Google Scholar : PubMed/NCBI
125	Basher F, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, Ji Z and Wu JD: Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 13:742020. View Article : Google Scholar : PubMed/NCBI
126	Narni-Mancinelli E and Vivier E: Shed NKG2D ligand boosts NK cell immunity. Cell Res. 25:651–652. 2015. View Article : Google Scholar : PubMed/NCBI
127	Yamanegi K, Yamane J, Kobayashi K, Ohyama H, Nakasho K, Yamada N, Hata M, Fukunaga S, Futani H, Okamura H and Terada N: Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. Oncol Rep. 28:1585–1590. 2012. View Article : Google Scholar : PubMed/NCBI
128	Miyashita T, Miki K, Kamigaki T, Makino I, Tajima H, Nakanuma S, Hayashi H, Takamura H, Fushida S, Ahmed AK, et al: Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B. Oncol Lett. 14:5918–5926. 2017.PubMed/NCBI
129	Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, et al: NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood. 111:1428–1436. 2008. View Article : Google Scholar : PubMed/NCBI
130	Ho TCS, Chan AHY and Ganesan A: Thirty years of HDAC inhibitors: 2020 Insight and hindsight. J Med Chem. 63:12460–12484. 2020. View Article : Google Scholar : PubMed/NCBI
131	Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR and Rossello A: Discovery of a new selective inhibitor of A disintegrin and metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models. Eur J Med Chem. 111:193–201. 2016. View Article : Google Scholar : PubMed/NCBI
132	Sekiba K, Otsuka M, Seimiya T, Tanaka E, Funato K, Miyakawa Y and Koike K: The fatty-acid amide hydrolase inhibitor URB597 inhibits MICA/B shedding. Sci Rep. 10:155562020. View Article : Google Scholar : PubMed/NCBI
133	Liu J and Khalil RA: Matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders. Prog Mol Biol Transl Sci. 148:355–420. 2017. View Article : Google Scholar : PubMed/NCBI
134	Huang B, Sikorski R, Sampath P and Thorne SH: Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother. 34:289–296. 2011. View Article : Google Scholar : PubMed/NCBI
135	Nwangwu CA, Weiher H and Schmidt-Wolf IGH: Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma. Hematol Oncol. 35:719–725. 2017. View Article : Google Scholar : PubMed/NCBI
136	Fuertes MB, Domaica CI and Zwirner NW: Leveraging NKG2D ligands in immuno-oncology. Front Immunol. 12:7131582021. View Article : Google Scholar : PubMed/NCBI
137	Xie X, Zhou Y, Wang X, Guo J, Li J, Fan H, Dou J, Shen B and Zhou C: Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo. Carbohydr Polym. 173:360–371. 2017. View Article : Google Scholar : PubMed/NCBI
138	Goto K, Arai J, Stephanou A and Kato N: Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10. Oncotarget. 9:18821–18831. 2018. View Article : Google Scholar : PubMed/NCBI